Compare MATV & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MATV | LBRX |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 701.0M | 563.2M |
| IPO Year | 1995 | 2025 |
| Metric | MATV | LBRX |
|---|---|---|
| Price | $12.16 | $22.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $49.00 |
| AVG Volume (30 Days) | 306.7K | ★ 508.7K |
| Earning Date | 02-18-2026 | 02-15-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,982,500,000.00 | N/A |
| Revenue This Year | $2.62 | N/A |
| Revenue Next Year | $2.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 0.39 | N/A |
| 52 Week Low | $4.34 | $13.36 |
| 52 Week High | $13.57 | $23.15 |
| Indicator | MATV | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | N/A |
| Support Level | $11.90 | N/A |
| Resistance Level | $12.45 | N/A |
| Average True Range (ATR) | 0.42 | 0.00 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 22.73 | 0.00 |
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments namely Filtration & advanced Materials focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging and healthcare solutions.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.